Unlike nausea, gastrointestinal motility changes often persist longersome patients experience mild diarrhea intermittently throughout weeks 2 to 6
The majority of GLP-1 medications are only approved for adults 18 years and older
You may not be surprised to learn that the study authors (all of whom, remember, take money from Novo Nordisk) characterized it differently: semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo. Lets talk about the study population
Insurance coverage expanded accordingly, though formulary restrictions and prior authorization requirements still limit immediate access for many patients
Gastrointestinal side effects remain among the most common challenges during GLP-1 therapy, with diarrhea reported in clinical studies at rates between 20-25% depending on dose and medication type
Xiang-Qun Hu, Xiao D, Zhu R, et al